This Biotech Skyrocketed 84% in 2 Days, But Is It Warranted?
Clinical-trial data can drive the valuation of biotech companies higher, but investors need to be able to recognize how much of the valuation increase is justified by the data and how much might be driven by external forces like a short squeeze. IGM Biosciences (NASDAQ: IGMS) seems to have experienced the latter after releasing data at the American Society of Hematology Annual Meeting earlier this month.
In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss what caused IGM's apparently unwarranted increase.
Source Fool.com
